Ascelia Pharma AB (OSTO:ACE) Total Receivables: kr3.28 Mil (As of Mar. 2026)


OSTO:ACE Ascelia Pharma AB OSTO:ACE
28 GF Score
Price kr2.96
! 1 Warning Sign
View Full Analysis

What is Ascelia Pharma AB Total Receivables?

Ascelia Pharma AB OSTO:ACE +1.02% 28 Total Receivables is kr3.28 Mil as of Mar. 2026. GuruFocus rates OSTO:ACE with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Ascelia Pharma AB's Total Receivables for the quarter that ended in Mar. 2026 was kr3.28 Mil.

Ascelia Pharma AB Total Receivables Related Terms

Ascelia Pharma AB Total Receivables Historical Data

* Premium members only.

The historical data trend for Ascelia Pharma AB's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascelia Pharma AB Total Receivables Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 0.43 1.39 0.58 4.51 1.40

Ascelia Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.46 3.40 2.61 1.40 3.28
OSTO:ACE
28GF Score
Ascelia Pharma AB OSTO:ACE
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ascelia Pharma AB Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of kr3.28 Mil mean?
Ascelia Pharma AB (OSTO:ACE) has a Total Receivables of kr3.28 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Ascelia Pharma AB and its competitors.
Is Ascelia Pharma AB's Total Receivables too high?
Ascelia Pharma AB's current Total Receivables is kr3.28 Mil. Overall, Ascelia Pharma AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Ascelia Pharma AB's Total Receivables compare to VRTX and REGN?
Ascelia Pharma AB's Total Receivables of kr3.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Ascelia Pharma AB and its competitors. Ascelia Pharma AB's current Total Receivables is kr3.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascelia Pharma AB stock overvalued right now?
Ascelia Pharma AB (OSTO:ACE) has a current Total Receivables of kr3.28 Mil. The current Total Receivables is kr3.28 Mil. Ascelia Pharma AB's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Ascelia Pharma AB (OSTO:ACE), the current Total Receivables is kr3.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Ascelia Pharma AB Business Description

Other Exchanges ACEs:UK
Address Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.
28GF Score

Get the complete analysis for OSTO:ACE

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.96
Price